RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline

RenovoRx (NASDAQ:RNXT) will use its H.C. Wainwright presentation to update investors on growing RenovoCath commercial demand, recent clinical evidence and the timeline toward Phase III TIGeR-PaC data.

Key Investor Takeaways

• RenovoRx (NASDAQ:RNXT) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, providing investors with updates across both its commercial and clinical programs.
• RenovoCath generated record quarterly revenue of $909,000 in Q2 2026, supported by increasing demand and repeat orders from high-volume cancer centers.
• The fully enrolled Phase III TIGeR-PaC trial remains on track for completion in the first half of 2027, with initial topline data expected in the second half.
• Recent TIGeR-PaC PK-PD data showed approximately 51% of the chemotherapy was extracted locally before entering the bloodstream, supporting the targeted-delivery rationale behind the TAMP platform.
• Investigator-initiated trials and the first commercial-center use of RenovoCath in a sarcoma patient may expand the clinical evidence supporting applications beyond locally advanced pancreatic cancer.

Why RNXT Stock Is in Focus

RenovoRx Chief Executive Shaun Bagai and Chief Financial Officer Mark Voll are scheduled to present at the H.C. Wainwright conference in New York on September 14 at 1:30 p.m. ET.

The presentation gives the company an opportunity to bring together two parts of its investment story: commercial adoption of its FDA-cleared RenovoCath device and progress toward a major Phase III oncology readout.

RenovoRx generated approximately $1.1 million from RenovoCath sales during its first full year of commercial activity in 2025. That was followed by record quarterly revenue of $909,000 in Q2 2026, with the company citing rising demand and repeat orders from existing customers.

Management will also discuss the first clinical use of RenovoCath in a sarcoma patient at CARTI Cancer Center Little Rock. The case provides another example of the device being used beyond the pancreatic cancer setting at the centre of RenovoRx’s late-stage clinical program.

The Phase III TIGeR-PaC trial reached full enrollment in August. The study is evaluating intra-arterial gemcitabine delivered through RenovoCath in patients with locally advanced pancreatic cancer, with completion expected during the first half of 2027 and initial topline results anticipated in the second half.

Why This Matters for Investors

The H.C. Wainwright presentation comes as RenovoRx develops a dual commercial and clinical narrative. RenovoCath is already generating standalone device revenue while the same delivery technology underpins the company’s investigational IAG drug-device combination.

That positioning may give investors multiple indicators of progress ahead of the TIGeR-PaC readout. Continued repeat ordering and adoption by additional medical institutions could provide evidence of commercial traction independently of the Phase III outcome.

Recent clinical evidence also adds context to the platform’s targeted-delivery strategy. An August 2026 peer-reviewed TIGeR-PaC sub-study found that TAMP-mediated delivery concentrated chemotherapy at the tumor site, with approximately 51% of the drug extracted locally before reaching the bloodstream.

The study also identified a statistically significant correlation between local drug metabolism and lower CA 19-9 levels. According to RenovoRx, the findings suggest improved tumor penetration and the potential to reduce systemic drug exposure and associated side effects.

For investors, however, the key clinical milestone remains the Phase III TIGeR-PaC readout. The IAG combination candidate remains investigational and has not been approved for commercial sale, meaning the 2027 data will be important to the future regulatory pathway.

What to Watch Next

Attention now turns to management’s September 14 presentation and any additional detail around RenovoCath commercial adoption, repeat ordering and expansion into new institutions.

Beyond the conference, the principal milestones are TIGeR-PaC trial completion in the first half of 2027 and initial topline data in the second half. Progress from investigator-initiated studies in borderline resectable and metastatic pancreatic cancer, along with the post-marketing registry study, could also broaden the evidence supporting the TAMP platform.

RenovoRx stock price